Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | MAPT | P10636 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 8/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206271 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL6227431 | 0.87 | MEN1 (0.74) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL6066774 | 0.87 | NPC1 (0.75) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL2682054 | 0.86 | KMT2A (1.00) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL5471126 | 0.86 | RAB9A (0.65) | KMT2AMAPTMEN1HTTALDH1A1 | |
| SCHEMBL4301183 | 0.85 | KMT2A (0.82) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL31206327 | 0.85 | MAPT (0.66) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL4548129 | 0.85 | MAPT (0.66) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL14459439 | 0.84 | KDR (0.76) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL12396048 | 0.83 | TRPV1 (0.73) | KMT2AMAPTMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | claimed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | claimed |
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | SALL4, SAV1, SUMO1 | KMT2A 972/4885MAPT 1091/4885MEN1 574/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | KMT2A 3423/4885MAPT 3890/4885MEN1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.